Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus lenvatinib versus placebo plus lenvatinib as first-line therapy for advanced hepatocellular carcinoma
2020-004437-20Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Toripalimab + lenvatinib with Placebo + lenvatinib (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Feb 2021; status: active.
02
Drugs
toripalimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-004437-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004437-20.